Efficacy and safety of perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for locally advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized phase III trials
Wirksamkeit und Sicherheit perioperativer Immun-Checkpoint-Inhibitoren plus Chemotherapie versus Chemotherapie allein bei lokal fortgeschrittenem Adenokarzinom des Magens oder des gastroösophagealen Übergangs: systematische Übersicht und Metaanalyse randomisierter Phase-III-Studien
Frontiers in Oncology · 17.03.2026 · 16
DOI: 10.3389/fonc.2026.1745875 ↗Auf einen Blick
Drei Phase-III-Studien mit 2.271 Patient:innen zeigen: Perioperative ICI plus Chemotherapie erhöhte die pCR-Rate gegenüber Chemotherapie allein. Schwere therapiebedingte Nebenwirkungen waren numerisch häufiger.
Fragestellung
Verbessern perioperative Immune-Checkpoint-Inhibitoren plus Chemotherapie im Vergleich zu Chemotherapie allein die Wirksamkeit und Sicherheit bei lokal fortgeschrittenem G/GEJ-Adenokarzinom?
Methode
Systematische Übersicht und Metaanalyse randomisierter Phase-III-Studien; random-effects für pCR, fixed-effect für Sicherheit; Heterogenität mit I².
Ergebnisse
3 Studien mit 2.271 Patient:innen. pCR: OR 4,04 (95 %-KI 2,60–6,27; p < 0,00001; I² = 49%). Grade ≥3 TRAEs: OR 1,61 (95 %-KI 0,96–2,71; p = 0,07; I² = 77%).
Schlussfolgerung der Autor:innen
Der Einsatz von ICIs in der perioperativen Chemotherapie verbesserte die pathologische Ansprechrate, ging aber mit einem erhöhten Risiko für Toxizitäten Grad ≥3 einher; die Autoren sehen dies als vielversprechende Strategie, vorbehaltlich reifer OS-Daten.
Kernaussagen
- pCR verbessert: OR 4,04 (95 %-KI 2,60–6,27)
- Grade ≥3 TRAEs numerisch häufiger: OR 1,61 (95 %-KI 0,96–2,71)
- Eingeschlossen: DRAGON IV, MATTERHORN, KEYNOTE-585
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 17.03.2026. Verfasst von Hai-Ting Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, Sichuan, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Phase III trials evaluating perioperative immune checkpoint inhibitors (ICIs) combined with chemotherapy for locally advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma have reported mixed efficacy results. We performed a systematic review and meta-analysis to synthesize the current evidence.
Methods
We systematically searched for randomized phase III trials comparing perioperative ICI plus chemotherapy with chemotherapy alone. Only phase III RCTs were included to minimize bias and avoid overestimation from phase II studies (see Methods for rationale).Primary outcomes were pathological complete response (pCR). Secondary outcomes were grade ≥3 treatment-related adverse events (TRAEs). Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using random-effects models for pCR due to clinical heterogeneity,fixed-effect models were used for safety as sensitivity. Heterogeneity was assessed using the I² statistic.
Results
Three trials (DRAGON IV, MATTERHORN, KEYNOTE-585) involving 2,271 patients were included. The addition of ICIs significantly improved the pCR rate (random-effects OR 4.04, 95% CI 2.60 to 6.27; p < 0.00001; I² = 49%). Grade ≥3 TRAEs were numerically higher in the ICI-chemotherapy group (OR 1.61, 95% CI 0.96 to 2.71; p = 0.07; I² = 77%).Sensitivity analysis excluding the TKI-containing DRAGON IV trial attenuated the toxicity estimate (OR 1.23,95% CI 0.71-2.14;I 2 = 58%).
Conclusion
The incorporation of ICIs into perioperative chemotherapy for locally advanced G/GEJ adenocarcinoma significantly enhances pathological response, albeit with an increased risk of grade ≥3 toxicities. These findings support perioperative ICI-chemotherapy as a promising and emerging strategy, pending confirmation from mature overall survival data.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, Sichuan, China.
- College of Clinical Medicine, Southwest Medical University, Luzhou, China.
- Department of General Surgery, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, Sichuan, China.
Zitieren
APA
Zhang, H. T., Xu, S. P., Xie, W. J., Li, J., Zhang, D. W., & Liu, K. (2026). Efficacy and safety of perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for locally advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized phase III trials. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1745875
Vancouver
Zhang HT, Xu SP, Xie WJ, Li J, Zhang DW, Liu K. Efficacy and safety of perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for locally advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized phase III trials. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1745875
BibTeX
@article{Zhang2026,
author = {Zhang, Hai-Ting and Xu, Sun-Peng and Xie, Wen-Jie and Li, Jian and Zhang, Di-Wen and Liu, Kuan},
title = {Efficacy and safety of perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for locally advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized phase III trials},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1745875}
}
EUVIMED